NCT05273138 Analysis of Dermal Fibroblasts and Immune Cells During Systemic Sclerosis
| NCT ID | NCT05273138 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Lille |
| Condition | Systemic Sclerosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2022-06-08 |
| Primary Completion | 2026-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2022-06-08 with a primary completion date of 2026-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The pathophysiology of systemic sclerosis (SSc) is still poorly understood and there are no effective treatments for this disease. SSc is a heterogeneous disease with varying severity. The heterogeneity of fibroblast profiles, observed in other fibrosing pathologies, has never been thoroughly explored in the skin of SSc patients. The immune system, and in particular B lymphocytes, plays a central role in the pathophysiology of SSc. The interactions between B lymphocytes and the cells responsible for excess collagen production, i.e. fibroblasts, are not fully elucidated The main objective is to analyze the heterogeneity of fibroblasts and infiltrating immune cells as well as their molecular signature in the skin of patients with SSc
Eligibility Criteria
Inclusion Criteria: * Man or woman over 18 years of age * With a systemic sclerosis meeting the ACR-EULAR 2013 criteria Having signed an informed consent * Being insured Exclusion Criteria: * Syndrome of overlap with another connective tissue disease according to the international diagnostic criteria * Immunosuppressive treatment within 12 months * Dosage of current corticosteroid therapy ≥10mg/d * Protected minors or adults * Pregnant or breastfeeding women * Deprived of their liberty * Persons in emergency situations * Persons who have refused or are unable to give informed consent
Contact & Investigator
David Launay, MD,PhD
PRINCIPAL INVESTIGATOR
University Hospital, Lille
Frequently Asked Questions
Who can join the NCT05273138 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Systemic Sclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05273138 currently recruiting?
Yes, NCT05273138 is actively recruiting participants. Contact the research team at david.launay@chru-lille.fr for enrollment information.
Where is the NCT05273138 trial being conducted?
This trial is being conducted at Lille, France.
Who is sponsoring the NCT05273138 clinical trial?
NCT05273138 is sponsored by University Hospital, Lille. The principal investigator is David Launay, MD,PhD at University Hospital, Lille. The trial plans to enroll 40 participants.